Last reviewed · How we verify
PLD
PLD is a pegylated liposomal doxorubicin that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to reduce systemic toxicity while maintaining anti-tumor efficacy.
PLD is a pegylated liposomal doxorubicin that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to reduce systemic toxicity while maintaining anti-tumor efficacy. Used for Ovarian cancer, Breast cancer, Multiple myeloma.
At a glance
| Generic name | PLD |
|---|---|
| Also known as | doxorubicin, caelyx, duomeisu, DOXIL, Caelyx, ATI-0918, doxorubicin hydrochloride liposome |
| Sponsor | AGO Research GmbH |
| Drug class | Pegylated liposomal chemotherapy |
| Target | DNA (topoisomerase II inhibitor via doxorubicin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The drug encapsulates doxorubicin in pegylated liposomes, which preferentially accumulate in tumor tissue through the enhanced permeability and retention (EPR) effect. This formulation reduces cardiotoxicity and other systemic side effects associated with free doxorubicin while preserving its DNA intercalation and topoisomerase II inhibition mechanisms. The pegylation extends circulation time and improves tumor targeting.
Approved indications
- Ovarian cancer
- Breast cancer
- Multiple myeloma
- Kaposi sarcoma
Common side effects
- Palmar-plantar erythrodysesthesia (hand-foot syndrome)
- Nausea and vomiting
- Stomatitis
- Myelosuppression
- Alopecia
- Cardiotoxicity
Key clinical trials
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (PHASE3)
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (PHASE3)
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLD CI brief — competitive landscape report
- PLD updates RSS · CI watch RSS
- AGO Research GmbH portfolio CI